PURPOSE: Assess the surgical complications of primary tumor resection in stage IV colon cancer patients previously treated with neoadjuvant chemotherapy. METHODS: Between July 2001 and September 2010, 67 consecutive patients received preoperative chemotherapy. Clinical and surgical complications were obtained from the medical records. This study was retrospective in design. RESULTS: All patients were affected with liver metastasis, and 29.8% had metastasis in additional organs. Three different schemes of preoperative chemotherapy were employed, based on FOLFIRI, XELOXIRI or XELOX plus cetuximab. Eighteen patients (26.8%) reported some side effects to the chemotherapy, without contraindicating any intervention. All patients underwent colon surgery and within those, eight patients (11.9%), underwent liver surgery simultaneously. Median hospital admission was 8 [3-29] days. The perioperative complication rate was 16.2%, when the estimated physiological and operative severity score for the enumeration of mortality and morbidity (POSSUM) was 58.3%. There was not perioperative mortality, despite the mortality prediction for Portsmouth-POSSUM (P-POSSUM) being 5.07%. No differences were observed between the chemotherapy regimen (P=0.72) or the kind of the surgery-simple or combined (P=0.58). CONCLUSIONS: Neoadjuvant chemotherapy as a systemic treatment for stage IV colon cancer does not indicate surgery contraindication nor increases postoperative morbimortality by a significant amount.
PURPOSE: Assess the surgical complications of primary tumor resection in stage IV colon cancerpatients previously treated with neoadjuvant chemotherapy. METHODS: Between July 2001 and September 2010, 67 consecutive patients received preoperative chemotherapy. Clinical and surgical complications were obtained from the medical records. This study was retrospective in design. RESULTS: All patients were affected with liver metastasis, and 29.8% had metastasis in additional organs. Three different schemes of preoperative chemotherapy were employed, based on FOLFIRI, XELOXIRI or XELOX plus cetuximab. Eighteen patients (26.8%) reported some side effects to the chemotherapy, without contraindicating any intervention. All patients underwent colon surgery and within those, eight patients (11.9%), underwent liver surgery simultaneously. Median hospital admission was 8 [3-29] days. The perioperative complication rate was 16.2%, when the estimated physiological and operative severity score for the enumeration of mortality and morbidity (POSSUM) was 58.3%. There was not perioperative mortality, despite the mortality prediction for Portsmouth-POSSUM (P-POSSUM) being 5.07%. No differences were observed between the chemotherapy regimen (P=0.72) or the kind of the surgery-simple or combined (P=0.58). CONCLUSIONS: Neoadjuvant chemotherapy as a systemic treatment for stage IV colon cancer does not indicate surgery contraindication nor increases postoperative morbimortality by a significant amount.
Entities:
Keywords:
Stage IV colon cancer; neoajuvant chemotherapy; physiological and operative severity score for the enumeration of mortality and morbidity (POSSUM); surgical morbidity
Authors: Arden M Morris; Laura-Mae Baldwin; Barbara Matthews; Jason A Dominitz; William E Barlow; Sharon A Dobie; Kevin G Billingsley Journal: Ann Surg Date: 2007-01 Impact factor: 12.969
Authors: E Maiello; V Gebbia; F Giuliani; G Paoletti; N Gebbia; N Borsellino; G Cartenì; G Pezzella; L Manzione; S Romito; M Lopez; G Colucci Journal: Ann Oncol Date: 2005-05 Impact factor: 32.976
Authors: René Adam; Robbert J de Haas; Dennis A Wicherts; Eric Vibert; Chadi Salloum; Daniel Azoulay; Denis Castaing Journal: Ann Surg Date: 2011-02 Impact factor: 12.969
Authors: Anthony J Senagore; Anthony J Warmuth; Conor P Delaney; Paris P Tekkis; Victor W Fazio Journal: Dis Colon Rectum Date: 2004-07-15 Impact factor: 4.585
Authors: Axel Andres; Christian Toso; Rene Adam; Eduardo Barroso; Catherine Hubert; Lorenzo Capussotti; Eric Gerstel; Arnaud Roth; Pietro E Majno; Gilles Mentha Journal: Ann Surg Date: 2012-11 Impact factor: 12.969
Authors: Heidi Nelson; Daniel J Sargent; H Sam Wieand; James Fleshman; Mehran Anvari; Steven J Stryker; Robert W Beart; Michael Hellinger; Richard Flanagan; Walter Peters; David Ota Journal: N Engl J Med Date: 2004-05-13 Impact factor: 91.245
Authors: J Arredondo; E Pastor; V Simó; M Beltrán; C Castañón; M C Magdaleno; I Matanza; M Notarnicola; B Ielpo Journal: Tech Coloproctol Date: 2020-07-14 Impact factor: 3.781
Authors: Elias Nerad; Andrea Delli Pizzi; Doenja M J Lambregts; Monique Maas; Sharan Wadhwani; Frans C H Bakers; Harrie C M van den Bosch; Regina G H Beets-Tan; Max J Lahaye Journal: PLoS One Date: 2019-02-05 Impact factor: 3.240